Fig. 2

HRs and 95% CIs for the association of pre-diagnostic use of metformin and WLM with all-cause and cancer-specific mortality among women 65 + years old with ORC. aHR, adjusted hazard ratio; CI, confidence interval; ORC, obesity-related cancers; WLM, weight loss medication. Multivariable Cox regressions (all-cause mortality) and Fine-Gray competing risks (cancer-specific mortality) models are adjusted for age at prescription, race/ethnicity, cancer stage, cancer grade, Charlson comorbidity index, diabetes, use of insulin, hypertension, hyperlipidemia, cardiovascular disease, malaise and fatigue, muscular wasting and atrophy, hypogonadism, anterior pituitary dysfunction, depression, osteoporosis, Cushing syndrome, hypothyroidism, hyperthyroidism, polycystic ovary syndrome, poverty rate. ^aDenotes statistical significance at the P-value < 0.05 level.